Wednesday, March 27, 2024 2:49:02 PM
If HMBL didn't think that they were on the hook for substantially more than $2.2mil, they wouldn't have paid it. The "hint" was a hint that I read the court document as I said there was a nondisclosure paragraph in there to keep Sharp from letting everyone know that HMBL screwed up concerning the toxic debt. You stated that I didn't read it. As if you would know what I read. To HMBL's defense, once the stock dropped to below a buck from it's high, there wasn't going to be any real financing to be had anyway. Foote talks about how hairy things got for a while and how they had to cut costs to the bone to stay afloat.
Why do you keep bringing up the RS but don't talk about the toxic debt? The RS was crappy because you never RS before major conversions take place. Had they done a 20 to 1 RS with the preferred being part of the RS, it could have worked, but they didn't do that. For you to repeatedly point to the RS as my reasoning means you cannot connect dots. The RS happened first. That was against Sharp's way of doing business unless necessary (he said so in several tweets). The toxic debt caused Sharp to quit. The rescinding of the toxic debt "bridge loan" with Brighton allowed Sharp to reconsider. The addition of Monmoth and other toxic loans caused him to quit again. Sharp reached out and offered $2mil in cash so that HMBL wouldn't need to borrow using toxic loans. They took the money and did the toxic debt anyway. This is not hard to understand.
I'd like to say that all this is in the past and HMBL is on its way to full recovery, but Pacific Lion or Foote or both are either lying or very confused. If they can figure a way out of the OS - whether it is a RS once the company has positive cash flow, or a stock repurchase plan, there is great hope. If the toxic debt can't be stopped, the only hope will be to catch the next few bounces on the way to the dead cat.
Recent HMBL News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 02:19:41 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 01/03/2024 05:00:32 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/06/2023 09:05:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2023 01:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 09:20:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/31/2023 01:15:12 PM
- Form 1-A - Offering Statement [Regulation A] • Edgar (US Regulatory) • 08/22/2023 07:48:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:14:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:53:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:15:09 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 06/30/2023 08:35:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM